Daniel Ferreira, Managing Director, Synova Licensing and Access

Daniel has 20 years of experience in Pharma. He served on the last years as the Portfolio and Alliances Director Latin America at Abbott where he was responsible for 355 new products (SKUs) introduced in 8 markets in Latin America, including Brazil, Mexico, Argentina and Colombia between 2017 and 2018. He was responsible to initiate the first Abbott’s EPD Division cross reginal deal involving Latin America, Asia (including China), Russia, Turkey and Arabic countries.

In March this year when he joined Pedro Serafin – CEO and owner of Synova Health, leading CRO in Latin America- and his colleague Ana Noboli to start Synova Licensing and Access in the capacity of Managing Director.

Synova L&A is a Pharmaceutical and Services company specialized in Oncology, Orphan Drugs and Medical Devices.

Previously he was Business Development Director Latin America at Merck Serono for 6 years, where he was responsible for 18 Products Licensed from 4 Companies adding Euro 22,8 Million in Sales. He was the key negotiator at the Merck-Lupin Global Strategic Alliance (Prize Granted by Merck Board). Deal Publicly announced in August 2014

Daniel has also served the Local Pharma Industry as BD and International Division Director at the EMS Group where Structured and Directed the International Division and lived in Milan-IT, between 2004 and 2009.

He developed partnerships with International Companies to launch different drugs including but not only: Agrylin (Shire-UK); Gynazole (KV-USA); and a co-Marketing agreement with Akzo Organon-NL (Hormones)

He organized the EMS international Pipeline coordinating the many departments involved on the task: Intellectual Property; Marketing Intelligence; Supply Chain; R & D; Financial and Production

He signed multiple License Out agreements for the Group in Europe, US and Middle East achieving in received License Fees up to Euro 9 million and circa Euro 60 million in Revenue/year between 2003 and 2008 .

He also conducted the process of Due Diligence and Acquisition of the following companies: Biomedica Foscama (Italy); Germed-Pliva (Italy); Edigen (Spain) and Monte Research (Italy)

Daniel has also started up and successfully exit from a Business Development and Regulatory platform in the Netherlands, where he lived for one year.